In vitro data indicate that imipramine (IMI), a widely used tricyclic antidepressant drug, is N-demethylated by several isoforms of cytochrome P450, which include CYP3A4. The aim of this study was to investigate the role of CYP3A in the in vivo N-demethylation of IMI. Methods Healthy subjects were given troleandomycin (TAO), a selective inhibitor of CYP3A, 250 mg daily for 2 days before a single oral dose of 100 mg IMI was administered. Troleandomycin is a macrolide antibiotic, which has been Imipramine (IMI) is a widely used tricyclic antidepressant drug [1], which is metabolized mainly by N-demethylation shown to inhibit in vitro human CYPs 3A3, 3A4 and 3A5 in human liver microsomes. The activity of seven other to its active metabolite desipramine (DMI) and by aromatic hydroxylation to 2-hydroxyimipramine and 10-hydroxy-CYP forms including CYP1A2 and CYP2C9 [18] was unaffected. Watkins and co-workers have shown that using imipramine [1, 2]. DMI is further oxidized to 2-hydroxydesipramine and 10-hydroxydesipramine [2]. These metathe erythromycin breath test, CYP3A activity [19] was inhibited by 80% by treatment with 250 mg oral TAO in bolic pathways are catalyzed by several liver microsomal cytochromes P450. A major problem in the clinical use of healthy volunteers [20] . Thus, the aim of this study was to investigate the effect of TAO on the pharmacokinetics of this drug is that the large interpatient variations in plasma concentrations of IMI and DMI may cause differences in IMI in vivo to assess the role of CYP3A in the Ndemethylation of IMI. clinical response and toxicity, particularly cardiotoxicity [1, 3]. The major source of this variation is considered to be the interindividual differences in activities of the Methods cytochromes P450 that catalyze IMI metabolism [4].
Introduction ytoin [14] [15] [16] .
Troleandomycin is a macrolide antibiotic, which has been Imipramine (IMI) is a widely used tricyclic antidepressant drug [1] , which is metabolized mainly by N-demethylation shown to inhibit in vitro human CYPs 3A3, 3A4 and 3A5 in human liver microsomes. The activity of seven other to its active metabolite desipramine (DMI) and by aromatic hydroxylation to 2-hydroxyimipramine and 10-hydroxy-CYP forms including CYP1A2 and CYP2C9 [18] was unaffected. Watkins and co-workers have shown that using imipramine [1, 2] . DMI is further oxidized to 2-hydroxydesipramine and 10-hydroxydesipramine [2] . These metathe erythromycin breath test, CYP3A activity [19] was inhibited by 80% by treatment with 250 mg oral TAO in bolic pathways are catalyzed by several liver microsomal cytochromes P450. A major problem in the clinical use of healthy volunteers [20] . Thus, the aim of this study was to investigate the effect of TAO on the pharmacokinetics of this drug is that the large interpatient variations in plasma concentrations of IMI and DMI may cause differences in IMI in vivo to assess the role of CYP3A in the Ndemethylation of IMI. clinical response and toxicity, particularly cardiotoxicity [1, 3]. The major source of this variation is considered to be the interindividual differences in activities of the Methods cytochromes P450 that catalyze IMI metabolism [4] .
Several studies have indicated that the 2-hydroxylation of Subjects IMI and DMI cosegregate with polymorphic CYP2D6
Nine male Chinese aged 21-28 years were enrolled into activity which is responsible for the oxidation of debrisoquine the study. All subjects were healthy as assessed by medical and sparteine [5, 7, 8 ]. However, the N-demethylation and history, physical examination, and routine laboratory tests. 10-hydroxylation of IMI are catalyzed partially by polyNone of them smoked tobacco products or received regular morphic S-mephenytoin 4∞-hydroxylase (CYP2C19) both medication and all subjects abstained from alcohol and in vivo and in vitro [9] [10] [11] . Furthermore, the rate of IMI Ngrapefruit juice during the study. The study protocol was demethylation correlated highly with CYP1A2 activity (r= approved by the Ethics Committee of Hunan Medical 0.88, P<0.001) and CYP3A4 activity (r=0.80, P<0.02) University and informed written consent was obtained from in human liver microsomal preparations [12] , and antibodies each subject. to CYP1A2 and CYP3A4 abolished 80% and 60% of Ndemethylase activity, respectively [12] . The involvement of CYP1A2 and CYP3A4 has also been confirmed by another Protocol report [13] . In vivo studies have shown that fluvoxamine, an
The study was performed in two randomized phases inhibitor of both CYP1A2 and CYP2C19, could inhibit separated by a washout period of 4 weeks. After an overnight fast, each subject was given 100 mg IMI (Huanghe occasions: (1) alone and (2) 2 h after 250 mg troleandomycin Pharmacokinetic analysis (Pfizer Inc., Tamsui, Taiwan) dosed orally once daily for 2 days. Venous blood samples (8 ml each) were collected into
The elimination half-life (t 1/2 ) of IMI was calculated from least squares regression of the log plasma drug concentration heparinized tubes from a forearm vein immediately before dosing and at 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120 h time profile. The area under the concentration-time curve (AUC) was calculated using the log linear trapezoidal rule after dosing. Plasma was separated immediately by centrifugation. Urine was collected from 0-48 h after IMI adminisand extrapolated to time infinity (AUC) using the elimination rate constant (l z ). The apparent oral clearance (CL o ) was tration. Plasma samples and urine samples were stored at −40°C until analysis.
calculated by dividing the dose by AUC.
Analysis of IMI and DMI Statistic analysis
Data are expressed as mean±s.d. with 95% confidence Both IMI and DMI were determined by gas chromatography using nitrogen phosphorus detection according to the intervals (CI) for the mean differences. Statistical evaluation was performed using paired t-test. A P value less than 0.05 method by Rovei et al. [21] with minor modifications. In brief, the working conditions were as follows: flow rate was required for rejection of the null hypothesis. 18.5 ml min −1 for nitrogen, 1.5 ml min −1 for hydrogen, 100 ml min −1 for air flow rate; temperature 245°C for Results column, 275°C for both detector and injector. The lower detection limits of the assay (signal5noise ratio≥3) were Table 1 summarizes the pharmacokinetics of IMI and its Ndemethylation metabolite DMI without and with TAO 2.5 ng ml −1 for IMI and DMI in plasma, 10 ng ml −1 for IMI and 15 ng ml −1 for DMI in urine. The intra-and pretreatment in nine subjects. Figure 1a shows the corresponding plasma concentration-time profiles. Pretreatment inter-day coefficients of variation (CV ) for IMI and DMI analysis were 9.2% and 11.8% in plasma and 7.8% and 13.5%
with TAO significantly increased the AUC of IMI by 59% (1971±938 vs 3134±2000 mg l −1 h, P<0.05), prolonged in urine, respectively. The combination of TAO and IMI was well tolerated by 346-364. the subjects, all of whom completed the study protocol. inhibitor of CYP3A [18] , the inhibitory effects of TAO on
